why choose us

First received: September 15, 2022

Clinical Trial: Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

Study Status: Completed

Recruit Status: RECRUITING

Condition: Neurotrophic Keratopathy

Study Type: INTERVENTIONAL


Official Title: A Phase 3, Multi-Center, Randomized, Parallel, Double Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic

Brief Summary: The objective of this study is to compare the safety and efficacy of RGN-259 to placebo for the treatment of Neurotrophic Keratopathy (NK)

Read more